« Back to Record
Citation APA

Shi, W., Jiang, T., Nuciforo, P., Hatzis, C., Holmes, E., Harbeck, N., Sotiriou, C., Peña, L., Loi, S., Rosa, D. D., Chia, S., Wardley, A., Ueno, T., Rossari, J., Eidtmann, H., Armour, A., Piccart-Gebhart, M., Rimm, D. D., Baselga, J., & Pusztai, L. (2018). Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial. Annals of oncology, 29(10), 2152. doi:10.1093/annonc/mdx805


Permalink

http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/283378

Shi, W., Jiang, T., Nuciforo, P., Hatzis, C., Holmes, E., Harbeck, N., Sotiriou, C., Peña, L., Loi, S., Rosa, D. D., Chia, S., Wardley, A., Ueno, T., Rossari, J., Eidtmann, H., Armour, A., Piccart-Gebhart, M., Rimm, D. D., Baselga, J., & Pusztai, L. (2018). Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial. Annals of oncology, 29(10), 2152. doi:10.1093/annonc/mdx805